114 related articles for article (PubMed ID: 2241112)
1. CA-125 monitoring in the management of ovarian cancer.
Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
3. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
Zaucha R; Kobierska A
Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
[TBL] [Abstract][Full Text] [Related]
4. CA 125 in ovarian cancer.
van der Burg ME; Lammes FB; Verweij J
Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185
[TBL] [Abstract][Full Text] [Related]
5. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
[TBL] [Abstract][Full Text] [Related]
6. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
10. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
Pearl ML; Yashar CM; Johnston CM; Reynolds RK; Roberts JA
Gynecol Oncol; 1994 Jun; 53(3):339-43. PubMed ID: 7911444
[TBL] [Abstract][Full Text] [Related]
11. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
12. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
13. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
15. Serological monitoring of epithelial ovarian cancer.
Fisken J; Leonard RC; Badley A; Jönrup I; Aspinall L; Sturgeon C; Roulston JE
Dis Markers; 1991; 9(3-4):175-90. PubMed ID: 1813209
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
19. [Computed tomography and tumor markers as diagnostic alternatives to second-look surgery in the treatment of malignant ovarian tumors].
La Fianza A; Campani R; Dore R; Babilonti L; Torretta L
Radiol Med; 1992 Apr; 83(4):374-82. PubMed ID: 1603993
[TBL] [Abstract][Full Text] [Related]
20. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
Markowska J; Kopczyński Z; Manyś G; Szewierski Z
Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]